Boehringer Ingelheim GmbH

ACTIVE

Boehringer Ingelheim

Binger Strasse 173, 55216 Ingelheim am Rhein, Germany, Ingelheim Am Rhein, Rheinland-Pfalz, 德国www.boehringer-ingelheim.comPrivate54,300 名员工成立于: 1885-01-01

别名:

boehringer-ingleheim

隶属于 C.H. Boehringer Sohn AG & Co. KG

German pharmaceutical company founded in 1885, one of the world's largest pharmaceutical firms; specializes in human pharmaceuticals, animal health, and biopharmaceuticals across respiratory diseases, oncology, and immunology. Wholly owned by the Boehringer, Liebrecht and von Baumbach families and not publicly listed.

概览

试验阶段分布

阶段

试验数

占比

1 期

28.6%

试验状态分布

进行中（未招募）

100.0%

相关临床试验

该机构主办的试验（7）

An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg + hydrochlorothiazide 25 mg tablets alone or in combination with other antihypertensive medications in patients with hypertension.

1 期

进行中（未招募）

Jan 2006700 名受试者

A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suffering from chronic venous insufficiency - Antistax study

进行中（未招募）

Dec 2005200 名受试者

A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suffering from chronic venous insufficiency - Antistax-Study

进行中（未招募）

Dec 2005200 名受试者

A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suffering from chronic venous insufficiency - Antistax-Study

进行中（未招募）

Oct 2005200 名受试者

.A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 weeks, compared to placebo, in community-dwelling elderly women = 65 years of age with symptoms of stress urinary incontinence or stress–predominant mixed urinary incontinence. - Active elderly

进行中（未招募）

Jul 2005276 名受试者

A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence

1 期

进行中（未招募）

Apr 20051000 名受试者

A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL) (4mg once daily) with placebo in patients with symptoms of Urge Urinary Incontinence

进行中（未招募）

Jan 20051000 名受试者

药物批准

暂无批准数据

资讯

ADME Toxicology Testing Market Outlook 2026-2030: North America Leads as Asia-Pacific Emerges as Fastest-Growing Region

- A new market outlook covering 2026-2030 projects continued growth in ADME toxicology testing demand, driven by expansion of the global pharmaceutical industry. - North America was the largest regional market in 2025, while Asia-Pacific is expected to be the fastest-growing region through the forecast period. - European pharmaceutical production reached EUR 390.0 billion ($422.8 billion) in 2023, up from EUR 363.3 billion ($393.9 billion) in 2022, according to EFPIA. - Evotec SE launched the Cyprotex e-Store in October 2023, an e-commerce platform providing online access to its ADME-Tox service portfolio.

Sep 14, 2026

返回机构列表